CD274 and non-small cell lung carcinoma: The median OS for first-line pembrolizumab monotherapy in PS0-1 advanced/metastatic NSCLC (mixed adenocarcinomas and squamous cell carcinomas) with PD-L1 expression ≥50% was 26.3 months in the KEYNOTE-024 study and 20.0 months in the KEYNOTE-042 study [6, 7].